Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization.

Stabilization and ease of administration are two ways to substantially improve the use of current vaccines. In the present study an influenza whole inactivated virus (WIV) vaccine was freeze-dried or spray-freeze dried in the presence of inulin as a cryoprotectant. Only spray-freeze drying rendered powders compatible with administration to the lungs by insufflation. Pulmonary administration of the powder vaccine obtained by this method to BALB/c mice led to a transient influx of neutrophils and a concomitant decrease in the number of macrophages as did administration of liquid vaccine. Inflammatory reactions to both vaccines were mild and short-lived. Immunization studies showed that the immunogenic properties of WIV vaccine were not affected by drying. Pulmonary administration of the powder WIV vaccine induced a systemic immune response of the same magnitude as liquid vaccine while mucosal IgA responses were higher for powder WIV. In a challenge study where immunized mice were exposed to a lethal dose of live virus, two pulmonary doses of either liquid or powder WIV vaccine were equally effective as a single intramuscular injection of subunit vaccine in terms of reduction of the viral load in the lungs. To conclude, in the models employed for these studies the use of a dry powder WIV vaccine for pulmonary immunization was shown to be safe and efficient.

[1]  W. Hinrichs,et al.  Needle-free influenza vaccination. , 2010, The Lancet. Infectious diseases.

[2]  J. Remon,et al.  Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. , 2009, Vaccine.

[3]  H. Frijlink,et al.  Inulin glasses for the stabilization of therapeutic proteins. , 2001, International journal of pharmaceutics.

[4]  M. Holtzman,et al.  Emerging role of dendritic cells in respiratory viral infection , 2007, Journal of Molecular Medicine.

[5]  E. Hamelmann,et al.  Influenza virus; , 2008 .

[6]  C. Coban,et al.  Plasmacytoid Dendritic Cells Delineate Immunogenicity of Influenza Vaccine Subtypes , 2010, Science Translational Medicine.

[7]  N. Low,et al.  Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. , 2008, Vaccine.

[8]  Katherine A. Fitzgerald,et al.  Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling , 2008, PLoS pathogens.

[9]  M. Dolovich,et al.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. , 2003, British journal of clinical pharmacology.

[10]  W. Hinrichs,et al.  Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. , 2007, Vaccine.

[11]  R. Compans,et al.  Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus , 2007, Journal of Virology.

[12]  C. Braun,et al.  Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[13]  M. Dolovich,et al.  Labiris NR, Dolovich MB. Pulmonary drug delivery: part II. the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications , 2004 .

[14]  W. Hinrichs,et al.  Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  F. Cutts,et al.  Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes. , 2000, The Pediatric infectious disease journal.

[16]  Clare L. Bennett,et al.  Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells , 2008, The Journal of experimental medicine.

[17]  J. Renauld,et al.  The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response , 2007, Immunology.

[18]  T. Randall,et al.  Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. , 2010, Nature immunology.

[19]  M. Ameri,et al.  Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. , 2004, Journal of pharmaceutical sciences.

[20]  K. Snibson,et al.  Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing , 2008, Mucosal Immunology.

[21]  T. Randall,et al.  Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8+ T cell responses to influenza , 2010, Nature Immunology.

[22]  Vincent J. Sullivan,et al.  Noninvasive delivery technologies: respiratory delivery of vaccines , 2006, Expert opinion on drug delivery.

[23]  J. Wilschut,et al.  Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs , 2008, Influenza and other respiratory viruses.

[24]  W. Hinrichs,et al.  The development of stable influenza vaccine powder formulations for new needle-free dosage forms , 2017 .

[25]  M. Prausnitz,et al.  Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin , 2009, PloS one.

[26]  Scott A. Brown,et al.  Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza , 2006, Clinical and Vaccine Immunology.

[27]  B. Bloom,et al.  Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies. , 2009, Tuberculosis.

[28]  H. Frijlink,et al.  Inulin is a promising cryo- and lyoprotectant for PEGylated lipoplexes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[29]  W. Jiskoot,et al.  Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. , 2008, Vaccine.

[30]  Vincent J. Sullivan,et al.  A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. , 2004, Vaccine.

[31]  H W Frijlink,et al.  A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[32]  A. Bot,et al.  Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. , 2003, Vaccine.

[33]  Oommen John,et al.  Measles Aerosol Vaccine Project , 2010 .

[34]  W. Hinrichs,et al.  Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures , 2010, The AAPS Journal.

[35]  N. Kondo,et al.  Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. , 2003, Vaccine.

[36]  L. Brown,et al.  Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. , 2009, Vaccine.

[37]  Taeg S. Kim,et al.  Respiratory Dendritic Cell Subsets Differ in Their Capacity to Support the Induction of Virus-Specific Cytotoxic CD8+ T Cell Responses , 2009, PloS one.

[38]  B. Laube,et al.  The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. , 2005, Respiratory care.

[39]  A. Hickey,et al.  Pulmonary vaccine delivery , 2007, Expert review of vaccines.

[40]  H. Staats,et al.  Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination , 2007, AAPS PharmSciTech.

[41]  H. Frijlink,et al.  Dry powder inhalers for pulmonary drug delivery , 2004, Expert opinion on drug delivery.